サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1497651

生物製剤市場：供給源、製品、適応症、エンドユーザー別-2024-2030年の世界予測

Biologics Market by Source (Mammalian, Microbial), Product (Antisense & RNAi Therapeutics, Monoclonal Antibodies, Recombinant Hormones or Proteins), Indication, End-user - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円
生物製剤市場：供給源、製品、適応症、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

生物製剤市場規模は2023年に4,057億6,000万米ドルと推定され、2024年には4,305億9,000万米ドルに達し、CAGR 6.39%で2030年には6,263億4,000万米ドルに達すると予測されています。

生物製剤はバイオメディカル分野に不可欠であり、様々な健康状態に対処するための生物由来の生物学的治療の開発、製造、流通に焦点を当てています。ワクチン、遺伝子治療、モノクローナル抗体などの製品は、がん、自己免疫疾患、遺伝病などの深刻な疾患の治療において極めて重要です。これらの治療はヘルスケア施設や、革新的な治療を必要とする患者にとって極めて重要です。生物製剤で治療可能な慢性疾患の有病率の上昇が、生物製剤市場の成長を促進しています。ヘルスケア・インフラへの投資の増加と医療費の増加は、先進的な生物学的製剤による治療へのアクセスを拡大し、市場成長の足がかりとなっています。製造コストの高さ、バイオシミラーとの競合の激化、流通に必要なロジスティクス、特にコールドチェーン要件が市場成長の妨げとなっています。個人の遺伝的体質に基づいてオーダーメイドの治療法を提供する個別化医療への傾斜の高まりは、市場成長の機会を生み出すと予想されます。生物製剤に関連したイノベーションを強化するためのバイオテクノロジー企業と学術団体との研究開発におけるパートナーシップの開拓は、市場の範囲を拡大すると予想されます。

主な市場の統計
基準年[2023］ 4,057億6,000万米ドル
予測年 [2024] 4,305億9,000万米ドル
予測年 [2030] 6,263億4,000万米ドル
CAGR（%） 6.39%

地域別インサイト

南北アメリカは、強力な研究枠組み、多額の投資、技術革新を奨励する強固な特許法によって、生物製剤市場において重要な地域となっています。さらに、アメリカはバイオテクノロジーの進歩を支持するヘルスケア政策に支えられ、生物製剤市場が確立されています。最近の動向としては、FDAによる希少疾患に対する生物学的治療法の承認促進があり、政府による重要な支持を示しています。南北アメリカの主要企業は常に合併・買収に取り組んでおり、この地域の成長と技術革新を後押ししています。欧州連合（EU）は、生物製剤に関する厳しい規制基準を示し、治療の高い安全性と有効性を確保しています。EUの消費者は持続可能で倫理的に開発された製品を重視し、企業はより環境に優しい技術や慣行を採用するよう影響を及ぼしています。欧州医薬品庁（EMA）は、生物製剤の承認プロセスを合理化するために加盟国間で積極的に調整を行い、新しい治療法の迅速な市場参入を後押ししています。中東・アフリカ地域は、湾岸諸国がヘルスケア・インフラや生物製剤分野に多額の投資を行っており、ダイナミックな情勢を呈しています。消費者の間では生物学的治療に対する認識と受容が高まっています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、生物製剤市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront（F）、Pathfinder（P）、Niche（N）、Vital（V）に分類されます。

市場シェア分析

市場シェア分析は、生物製剤市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査対象期間の累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、生物製剤市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で慢性疾患の罹患率が上昇
      • 低侵襲手術に対するニーズと好みの高まり
    • 抑制要因
      • 生物製剤に関連する治療費の高騰
    • 機会
      • 慢性疾患の治療を改善する生体材料の継続的な進歩
      • 生物製剤に関連する製造施設の拡大
    • 課題
      • 生物製剤の複合製造の可用性
  • 市場セグメンテーション分析
    • 出典：哺乳類細胞はより大きく複雑なタンパク質を生産するのに適している
    • 適応症： COVID-19パンデミックとがん研究の進化によって推進される腫瘍学および感染症における継続的なイノベーション
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 生物製剤市場：ソース別

  • 哺乳類
  • 微生物

第7章 生物製剤市場：製品別

  • アンチセンスおよびRNAi治療薬
  • モノクローナル抗体
  • 組み換えホルモンまたはタンパク質
  • ワクチン

第8章 生物製剤市場適応症別

  • 心血管疾患
  • 血液疾患
  • 免疫疾患
  • 感染症
  • 腫瘍学

第9章 生物製剤市場：エンドユーザー別

  • 外来手術センター
  • 病院

第10章 南北アメリカの生物製剤市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の生物製剤市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの生物製剤市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • FDAが初のトシリズマブバイオシミラーTOFIDENCEを承認、自己免疫疾患治療へのアクセスを強化
    • イーライリリー、アイルランドの生物製剤製造施設への投資を拡大
    • サンドス、スロベニアの新施設への大規模投資を発表
  • 戦略分析と提言

第14章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BIOLOGICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY MAMMALIAN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY MICROBIAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY ANTISENSE & RNAI THERAPEUTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY ANTISENSE & RNAI THERAPEUTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT HORMONES OR PROTEINS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT HORMONES OR PROTEINS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 353. TURKEY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 354. TURKEY BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 355. TURKEY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 356. TURKEY BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 357. TURKEY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 358. TURKEY BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 359. TURKEY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 360. TURKEY BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 365. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 366. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 367. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 368. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 369. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 370. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 372. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 373. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 374. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 375. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 376. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 377. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 378. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-4302AC72200D

[180 Pages Report] The Biologics Market size was estimated at USD 405.76 billion in 2023 and expected to reach USD 430.59 billion in 2024, at a CAGR 6.39% to reach USD 626.34 billion by 2030.

Biologics are integral to the biomedical sector, focusing on developing, manufacturing, and distributing biological treatments derived from living organisms to combat various health conditions. Products, including vaccines, gene therapies, and monoclonal antibodies, are pivotal in treating serious ailments such as cancer, autoimmune disorders, and genetic diseases. These treatments are crucial in healthcare facilities and also for patients in need of innovative therapies. The rising prevalence of chronic diseases that can be treated with biologics is driving the growth of the biologics market. Increasing investments in healthcare infrastructure and an increase in healthcare spending are widening the accessibility of advanced biologic treatments, creating a platform for market growth. High manufacturing costs, rising competition from biosimilars, and demanding logistics for distribution, particularly cold chain requirements hampers the market growth. A rising inclination toward personalized medicine that provides tailored therapies based on individual genetic makeup is expected to create opportunities for market growth. Growing partnerships in research and development between biotech companies and academic entities to enhance innovation associated with biologics are anticipated to expand the market scope.

KEY MARKET STATISTICS
Base Year [2023] USD 405.76 billion
Estimated Year [2024] USD 430.59 billion
Forecast Year [2030] USD 626.34 billion
CAGR (%) 6.39%

Regional Insights

The Americas represents a significant region in the biologics market, driven by strong research frameworks, substantial investments, and robust patent laws that encourage innovation. Additionally, America has a well-established biologics market supported by healthcare policies that favor biotechnological advancements. Recent trends include the FDA's accelerated approval of biological treatments for rare diseases, showcasing a significant government endorsement. Key players in the Americas are consistently engaging in mergers and acquisitions, bolstering growth and innovation in this region. The European Union exhibits stringent regulatory standards for biologics, ensuring high safety and efficacy of treatments. Consumers in the EU focus on sustainable and ethically developed products, influencing companies to adopt greener technologies and practices. The European Medicines Agency (EMA) actively coordinates across member states to streamline the approval processes for biologics, fueling rapid market entry of new therapies. The Middle East and Africa region presents a dynamic landscape, with Gulf countries investing heavily in healthcare infrastructure and the biologics sector. There is a growing awareness and acceptance of biological treatments among consumers.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Biologics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising prevalence of chronic diseases worldwide
      • Growing need and preference for minimally invasive procedures
    • Market Restraints
      • High cost of treatment associated with biologics
    • Market Opportunities
      • Ongoing advancements in biomaterials improving the treatment of chronic disorders
      • Rising expansion of manufacturing facilities associated with biologics
    • Market Challenges
      • Availability of complex manufacturing of biologics
  • Market Segmentation Analysis
    • Source: Mammalian cells are preferable for producing larger and more complex proteins
    • Indication: Ongoing innovations in oncology and infectious diseases driven by the COVID-19 pandemic and cancer research's evolution
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biologics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biologics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves First Tocilizumab Biosimilar, TOFIDENCE, Enhancing Access to Treatment for Autoimmune Diseases

Biogen Inc. announced that TOFIDENCE (tocilizumab-bavi), a biosimilar to the monoclonal antibody ACTEMRA, has received U.S. FDA approval for intravenous use in treating moderately to severely active rheumatoid arthritis, as well as polyarticular and systemic juvenile idiopathic arthritis. This marks the first tocilizumab biosimilar cleared in the United States, potentially offering significant cost savings and wider therapy accessibility. The approval is pivotal, considering the annual 10%-25% increase in spending on autoimmune treatments over the last decade. [Published On: 2023-09-29]

Eli Lilly Expands Investment in Irish Biologics Manufacturing Facility

Eli Lilly invested in its biologics production facility, which is currently under construction in Raheen, Limerick County, Ireland. Eli Lilly injected an additional USD 500 million into the site, elevating its total expenditure to approximately 927 million USD 1 billion. [Published On: 2023-03-26]

Sandoz Announces Major Investment in New Biologics Facility in Slovenia

Sandoz invested over USD 400 million to construct a new biologics production facility in Lendava, Slovenia. This strategic development is aimed at bolstering the company's biosimilar portfolio. The construction underscores Sandoz's commitment to expanding its global presence while significantly contributing to local economic growth. [Published On: 2023-03-10]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biologics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Biologics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Biogen Inc., BioPharm Laboratories, LLC, Bristol Myers Squibb Company, Catalent, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Source
    • Mammalian
    • Microbial
  • Product
    • Antisense & RNAi Therapeutics
    • Monoclonal Antibodies
    • Recombinant Hormones or Proteins
    • Vaccines
  • Indication
    • Cardiovascular Disorders
    • Hematological Disorders
    • Immunological Disorders
    • Infectious Diseases
    • Oncology
  • End-user
    • Ambulatory Surgical Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases worldwide
      • 5.1.1.2. Growing need and preference for minimally invasive procedures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment associated with biologics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in biomaterials improving the treatment of chronic disorders
      • 5.1.3.2. Rising expansion of manufacturing facilities associated with biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of complex manufacturing of biologics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Source: Mammalian cells are preferable for producing larger and more complex proteins
    • 5.2.2. Indication: Ongoing innovations in oncology and infectious diseases driven by the COVID-19 pandemic and cancer research's evolution
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Biologics Market, by Source

  • 6.1. Introduction
  • 6.2. Mammalian
  • 6.3. Microbial

7. Biologics Market, by Product

  • 7.1. Introduction
  • 7.2. Antisense & RNAi Therapeutics
  • 7.3. Monoclonal Antibodies
  • 7.4. Recombinant Hormones or Proteins
  • 7.5. Vaccines

8. Biologics Market, by Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Disorders
  • 8.3. Hematological Disorders
  • 8.4. Immunological Disorders
  • 8.5. Infectious Diseases
  • 8.6. Oncology

9. Biologics Market, by End-user

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals

10. Americas Biologics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biologics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biologics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves First Tocilizumab Biosimilar, TOFIDENCE, Enhancing Access to Treatment for Autoimmune Diseases
    • 13.3.2. Eli Lilly Expands Investment in Irish Biologics Manufacturing Facility
    • 13.3.3. Sandoz Announces Major Investment in New Biologics Facility in Slovenia
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio